Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG).

Hoda MA, Klikovits T, Arns M, Dieckmann K, Zöchbauer-Müller S, Geltner C, Baumgartner B, Errhalt P, Machan B, Pohl W, Hutter J, Eckmayr J, Studnicka M, Flicker M, Cerkl P, Klepetko W.

Wien Klin Wochenschr. 2016 Sep;128(17-18):618-26. doi: 10.1007/s00508-016-1036-3.

2.

Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group.

Miller DS, Blessing JA, Ramondetta LM, Pham HQ, Tewari KS, Landrum LM, Brown J, Mannel RS.

J Clin Oncol. 2014 Sep 1;32(25):2744-9. doi: 10.1200/JCO.2013.54.7448.

3.

Current issues in malignant pleural mesothelioma evaluation and management.

Ai J, Stevenson JP.

Oncologist. 2014 Sep;19(9):975-84. doi: 10.1634/theoncologist.2014-0122.

4.

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM.

Lung Cancer. 2014 Jun;84(3):271-4. doi: 10.1016/j.lungcan.2014.03.006.

5.

Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.

Neumann V, Löseke S, Nowak D, Herth FJ, Tannapfel A.

Dtsch Arztebl Int. 2013 May;110(18):319-26. doi: 10.3238/arztebl.2013.0319. Review.

6.

Current therapies for malignant pleural mesothelioma.

Nakano T.

Environ Health Prev Med. 2008 Mar;13(2):75-83. doi: 10.1007/s12199-007-0016-7.

7.

Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.

Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke M.

J Occup Med Toxicol. 2008 Dec 18;3:34. doi: 10.1186/1745-6673-3-34.

8.
9.

BTS statement on malignant mesothelioma in the UK, 2007.

British Thoracic Society Standards of Care Committee..

Thorax. 2007 Nov;62 Suppl 2:ii1-ii19. No abstract available.

Items per page

Supplemental Content

Support Center